Mylan (MYL +0.9%) gets a boost today from an upgrade to Outperform at Leerink Swann, citing a...

|About: Mylan Inc (MYL)|By:, SA News Editor

Mylan (MYL +0.9%) gets a boost today from an upgrade to Outperform at Leerink Swann, citing a better outlook for EpiPen sales and optimism over the company's 2013 guidance. The firm ups its price target to $30 from $26.